We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




World’s First Rapid POC Diagnostic Test Could Detect ‘Insidious’ Malaria Infections

By LabMedica International staff writers
Posted on 07 Feb 2023

Each year, there are over 200 million cases of malaria and about 620,000 deaths across the world. More...

Malaria is caused by the Plasmodium vivax parasite, which gets transmitted to humans via the bite of an infected mosquito. The Plasmodium vivax parasite poses a challenge as it can remain dormant in the liver for years, but reawaken later to continue spreading the disease. Now, new research aims to develop and deploy the world’s first diagnostic test for detecting 'insidious' malaria infections and accelerating malaria eradication.

Two projects by The Walter and Eliza Hall Institute of Medical Research (WEHI, Melbourne, Australia) have received new funding from the National Health and Medical Research Council (NHMRC, Canberra, Australia) to develop and deploy a test that is capable of detecting people with ‘hidden’ Plasmodium vivax. This malaria parasite is still the most widespread and resilient due to its ability to stay dormant in the liver for years. The funding will aid the development of the first such point-of-care rapid diagnostic test and deployment of its laboratory version in the Philippines.

The WEHI researchers had earlier developed a test that can accurately tell when an individual has been infected with the parasite and if there is a risk of relapse. The team will now develop a rapid point-of-care diagnostic test based on this earlier research. The researchers will first deploy a high throughput, laboratory version of the diagnostic test in the Philippines. They will leverage the expertise of research teams in the U.S. and Philippines to adopt a multi-disciplinary approach in order to focus their efforts on the Sultan Kudarat province where there have been Plasmodium vivax outbreaks recently.

In order to efficiently eliminate the Plasmodium vivax parasite, malaria control programs need tools to detect areas where there is ongoing transmission, and identify and treat people with dormant infections. The new test could be a game-changer for malaria control programs which have been struggling for decades to eliminate this relapsing parasite, according to the researchers. The team hopes that their research could assist in malaria eradication in the Philippines, as well as across East Asia. The generated data could be used to shape locally suitable and evidence-based interventions for improving the Philippines’ health policies.

“Being able directly target hidden liver-stage parasites is crucial for successful vivax elimination because they can be responsible for over 80% of all blood-stage infections. Unfortunately, there are currently no tests that can accurately detect who is carrying this insidious parasite in their bodies,” said Professor Ivo Mueller, a world expert in the biology, epidemiology and control of P. vivax malaria. “Our test is the closest the scientific world has come to tracking and predicting these ‘hidden’ infections and we are thrilled to start translating these findings to a rapid diagnostic test to improve the lives of those affected by the malarial health burden.”

Related Links:
WEHI
NHMRC


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
D-Dimer Test
Epithod 616 D-Dimer Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.